Intravitreal Ranibizumab Treatment of Macular Choroidal Neovascularization Secondary to Angioid Streaks

Abstract

Intravitreal ranibizumab is highly effective in improving or stabilizing vision and lesion morphology in patients with macular choroidal neovascularization secondary to angioid streaks.

Long-Term Follow-Up of Choroidal Neovascularization due to Angioid Streaks with pro re nata Intravitreal Anti-VEGF Treatment

“…Similar results after a longer follow-up were reported by Martinez-Serrano et al [45] in 14 eyes. In contrast, our data disagree with the data obtained by Sawa et al [31] , Finger et al [34] , El Matri et al [35] , Mimoun et al [24] , Ladas et al [37] , and Shah et al [40] , who demonstrated a trend for improvement or stability of functional and anatomical outcomes in their case series. In the study by Ladas et al [37] , eyes were treated according to a treatand-extend protocol, showing beneficial results with a mean of 7.1 injections over a 16-month period.…”

“…Our data showed a lower number of injections. This could be explained by the PRN regimen used in our case series compared with the different retreatment protocol used by Ladas et al [37] . We think that a treat-and-extend protocol may allow better visual and anatomical results, but it imposes a higher burden of intravitreal treatments on patients.…”

“…We think that a treat-and-extend protocol may allow better visual and anatomical results, but it imposes a higher burden of intravitreal treatments on patients. Explaining these differences in results is difficult, but we think that the different selection criteria for cases (naïve/not naïve, extra/juxta/subfoveal CNV), different durations of follow-up, and different treatment regimens used (PRN protocol [24,31,34,35,40,45] , single injection followed by a PRN protocol [41] , and treat-and-extend protocol [37] ) certainly played an important role. In fact, our results show a strong tendency towards relapse and confirm the difficulties in controlling a disease that deteriorates in the long term despite a close follow-up, especially in the case of subfoveal CNV and in eyes with a low baseline visual acuity.…”

Intravitreal ranibizumab for the treatment of choroidal neovascularisation secondary to angioid streaks

“…[24][25][26][27] Previous studies have demonstrated that ranibizumab has a prolonged effect in either stabilising or improving vision in CNV secondary to AS. 13 19 Vadalà et al 20 reported a series of nine patients who received 0.3 mg ranibizumab injections with a mean follow-up of 14 months. Mean visual acuity increased significantly with eight (88.9%) of the nine patients demonstrating an improvement or stabilisation in vision.…”

“…However, most of these studies are limited to single case reports, small numbers of patients or have limited/short follow-up. [16][17][18][19][20][21][22] We report a retrospective case series that assesses the medium to long-term efficacy and safety of intravitreal ranibizumab in patients with CNV secondary to AS.…”